Blincyto (blinatumomab)

pCPA File Number: 20972

Negotiation Status:

Concluded with an LOI

Indication(s):

Acute Lymphoblastic Leukemia (ALL)

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

PC0097-000

pCPA Engagement Letter Issued:

2017-12-29

Negotiation Process Concluded:

2019-01-15